{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:40:09Z","timestamp":1745206809901,"version":"3.40.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40268-024-00502-5","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T02:59:30Z","timestamp":1737428370000},"page":"57-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-6000","authenticated-orcid":false,"given":"Yi","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youpeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"502_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Van Der Ploeg","year":"2008","unstructured":"Van Der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372:1342\u201353.","journal-title":"Lancet"},{"key":"502_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","volume":"7","author":"MG Ausems","year":"1999","unstructured":"Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7:713\u20136.","journal-title":"Eur J Hum Genet"},{"key":"502_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jes\u00fas VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379:335\u201341.","journal-title":"Lancet"},{"key":"502_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ajmg.a.36197","volume":"164A","author":"C-F Yang","year":"2014","unstructured":"Yang C-F, Liu H-C, Hsu T-R, Tsai F-C, Chiang S-F, Chiang C-C, et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A. 2014;164A:54\u201361.","journal-title":"Am J Med Genet A"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s12035-019-01820-5","volume":"57","author":"AS Bellotti","year":"2020","unstructured":"Bellotti AS, Andreoli L, Ronchi D, Bresolin N, Comi GP, Corti S. Molecular approaches for the treatment of Pompe disease. Mol Neurobiol. 2020;57:1259\u201380.","journal-title":"Mol Neurobiol"},{"key":"502_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21037\/atm.2019.04.15","volume":"7","author":"HV Do","year":"2019","unstructured":"Do HV, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med. 2019;7:291.","journal-title":"Ann Transl Med."},{"key":"502_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23:1138\u201348.","journal-title":"Mol Ther"},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21037\/atm.2019.04.67","volume":"7","author":"G Ronzitti","year":"2019","unstructured":"Ronzitti G, Collaud F, Laforet P, Mingozzi F. Progress and challenges of gene therapy for Pompe disease. Ann Transl Med. 2019;7:287.","journal-title":"Ann Transl Med."},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ymthe.2017.05.019","volume":"25","author":"E Goina","year":"2017","unstructured":"Goina E, Peruzzo P, Bembi B, Dardis A, Buratti E. Glycogen reduction in myotubes of late-onset Pompe disease patients using antisense technology. Mol Ther. 2017;25:2117\u201328.","journal-title":"Mol Ther"},{"key":"502_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","volume":"15","author":"L Kohler","year":"2018","unstructured":"Kohler L, Puertollano R, Raben N. Pompe disease: from basic science to therapy. Neurotherapeutics. 2018;15:928\u201342.","journal-title":"Neurotherapeutics"},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"1280490","DOI":"10.3389\/fphar.2023.1280490","volume":"14","author":"H Li","year":"2023","unstructured":"Li H, Wang C, Deng A, Guo C. A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system. Front Pharmacol. 2023;14:1280490.","journal-title":"Front Pharmacol"},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist M, St\u00e5hl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23:533\u201342.","journal-title":"Drug Saf"},{"key":"502_CR13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362:1396\u2013406.","journal-title":"N Engl J Med"},{"key":"502_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","volume":"6","author":"IAM Ditters","year":"2022","unstructured":"Ditters IAM, Huidekoper HH, Kruijshaar ME, Rizopoulos D, Hahn A, Mongini TE, et al. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. Lancet Child Adolesc Health. 2022;6:28\u201337.","journal-title":"Lancet Child Adolesc Health."},{"key":"502_CR15","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","volume":"99","author":"MM Dimachkie","year":"2022","unstructured":"Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, et al. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease. Neurology. 2022;99:e536\u201348.","journal-title":"Neurology"},{"key":"502_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Lafor\u00eat P, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20:1027\u201337.","journal-title":"Lancet Neurol"},{"key":"502_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26\u201333.","journal-title":"Mol Genet Metab"},{"key":"502_CR18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/gim.2015.6","volume":"17","author":"KL Berrier","year":"2015","unstructured":"Berrier KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanescu MC, et al. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015;17:912\u20138.","journal-title":"Genet Med"},{"key":"502_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng Y-K, Kobori JA, Finkel RS, Ladda RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13:729\u201336.","journal-title":"Genet Med"},{"key":"502_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/gim.2016.70","volume":"19","author":"JM de Vries","year":"2017","unstructured":"de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, et al. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med. 2017;19:90\u20137.","journal-title":"Genet Med"},{"key":"502_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ymgme.2019.07.013","volume":"128","author":"E Fern\u00e1ndez-Sim\u00f3n","year":"2019","unstructured":"Fern\u00e1ndez-Sim\u00f3n E, Carrasco-Rozas A, Gallardo E, Gonz\u00e1lez-Quereda L, Alonso-P\u00e9rez J, Belmonte I, et al. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT. Mol Genet Metab. 2019;128:129\u201336.","journal-title":"Mol Genet Metab"},{"key":"502_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clim.2019.01.009","volume":"200","author":"AS De Groot","year":"2019","unstructured":"De Groot AS, Kazi ZB, Martin RF, Terry FE, Desai AK, Martin WD, et al. HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). Clin Immunol. 2019;200:66\u201370.","journal-title":"Clin Immunol"},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","volume":"106","author":"TT Patel","year":"2012","unstructured":"Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab. 2012;106:301\u20139.","journal-title":"Mol Genet Metab"},{"key":"502_CR24","volume":"20","author":"AK Desai","year":"2019","unstructured":"Desai AK, Kazi ZB, Bali DS, Kishnani PS. Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol Genet Metab Rep. 2019;20: 100475.","journal-title":"Mol Genet Metab Rep."},{"key":"502_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94328","volume":"2","author":"ZB Kazi","year":"2017","unstructured":"Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017;2: e94328.","journal-title":"JCI Insight."},{"key":"502_CR26","doi-asserted-by":"publisher","first-page":"1336599","DOI":"10.3389\/fimmu.2024.1336599","volume":"15","author":"H-A Chen","year":"2024","unstructured":"Chen H-A, Hsu R-H, Fang C-Y, Desai AK, Lee N-C, Hwu W-L, et al. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy. Front Immunol. 2024;15:1336599.","journal-title":"Front Immunol"},{"key":"502_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86821","volume":"1","author":"ZB Kazi","year":"2016","unstructured":"Kazi ZB, Prater SN, Kobori JA, Viskochil D, Bailey C, Gera R, et al. Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. JCI Insight. 2016;1: e86821.","journal-title":"JCI Insight."},{"key":"502_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymgme.2017.05.006","volume":"122","author":"M Rairikar","year":"2017","unstructured":"Rairikar M, Kazi ZB, Desai A, Walters C, Rosenberg A, Kishnani PS. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. Mol Genet Metab. 2017;122:76\u20139.","journal-title":"Mol Genet Metab"},{"key":"502_CR29","doi-asserted-by":"publisher","first-page":"1360369","DOI":"10.3389\/fimmu.2024.1360369","volume":"15","author":"AK Desai","year":"2024","unstructured":"Desai AK, Shrivastava G, Grant CL, Wang RY, Burt TD, Kishnani PS. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation. Front Immunol. 2024;15:1360369.","journal-title":"Front Immunol"},{"key":"502_CR30","first-page":"11995","volume":"10","author":"L Xu","year":"2017","unstructured":"Xu L, Zhang L, Zhong L, Huang X, Li S, Cheng Y, et al. A novel compound heterozygous GAA mutation in a Chinese family with juvenile onset form of Pompe disease with cardiomyopathy. Int J Clin Exp Pathol. 2017;10:11995\u20132002.","journal-title":"Int J Clin Exp Pathol"},{"key":"502_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40248-018-0145-4","volume":"13","author":"F Menzella","year":"2018","unstructured":"Menzella F, Codeluppi L, Lusuardi M, Galeone C, Valzania F, Facciolongo N. Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report. Multidiscip Respir Med. 2018;13:32.","journal-title":"Multidiscip Respir Med."},{"key":"502_CR32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2147\/TCRM.S362871","volume":"19","author":"L El Haddad","year":"2023","unstructured":"El Haddad L, Khan M, Soufny R, Mummy D, Driehuys B, Mansour W, et al. Monitoring and management of respiratory function in Pompe disease: current perspectives. Ther Clin Risk Manag. 2023;19:713\u201329.","journal-title":"Ther Clin Risk Manag"},{"key":"502_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10875-013-9902-5","volume":"33","author":"P Costa-Reis","year":"2013","unstructured":"Costa-Reis P, Sullivan KE. Chronic recurrent multifocal osteomyelitis. J Clin Immunol. 2013;33:1043\u201356.","journal-title":"J Clin Immunol"},{"key":"502_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11926-020-00928-1","volume":"22","author":"CM Hedrich","year":"2020","unstructured":"Hedrich CM, Morbach H, Reiser C, Girschick HJ. New insights into adult and paediatric chronic non-bacterial osteomyelitis CNO. Curr Rheumatol Rep. 2020;22:52.","journal-title":"Curr Rheumatol Rep"},{"key":"502_CR35","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021;20:1012\u201326.","journal-title":"Lancet Neurol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00502-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:14:04Z","timestamp":1745205244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00502-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00502-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"10 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yi Yin, Jie Jiang, and Youpeng Jin have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets supporting the conclusions of this article are included within the article. The underlying datasets are available from the corresponding authors on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code used and\/or analyzed during the current study is available from the corresponding authors on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"YY and JJ conceptualized the study concept and design. YY and JJ conducted the research; YY analyzed the data; YY and JJ drafted the manuscript. All authors were involved in writing the paper and had final approval of the submitted and published versions.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}